Anika Therapeutics (NASDAQ:ANIK) will post its quarterly earnings results after the market closes on Wednesday, February 21st. Analysts expect Anika Therapeutics to post earnings of $0.44 per share for the quarter.
Anika Therapeutics (NASDAQ:ANIK) opened at $57.24 on Wednesday. Anika Therapeutics has a 52-week low of $41.64 and a 52-week high of $69.81. The firm has a market capitalization of $839.24, a P/E ratio of 27.00, a P/E/G ratio of 3.49 and a beta of 1.60.
In other Anika Therapeutics news, insider Richard Hague sold 5,250 shares of the stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $54.48, for a total transaction of $286,020.00. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 6.57% of the company’s stock.
A number of research analysts recently weighed in on the company. BidaskClub raised Anika Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, January 26th. Sidoti started coverage on Anika Therapeutics in a research report on Friday, January 26th. They set a “buy” rating for the company. First Analysis upgraded Anika Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $45.00 to $68.00 in a research note on Wednesday, January 24th. Finally, Barrington Research reiterated a “buy” rating and set a $57.00 target price on shares of Anika Therapeutics in a research note on Thursday, December 28th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $62.50.
TRADEMARK VIOLATION WARNING: This story was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/02/14/anika-therapeutics-anik-set-to-announce-earnings-on-wednesday.html.
About Anika Therapeutics
Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.
Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.